Most leadership teams selling into regulated markets are not short of activity. They have a business development function, a marketing calendar, a stack of decks tailored to different buyers, and a growing list of intermediaries who each promise a way through. What they are usually short of is judgement: someone senior enough, and close enough to the actual business, to say which of those activities is worth the leadership team's time and which is noise dressed up as progress.
This distinction matters more in regulated markets than almost anywhere else. In an unregulated commercial environment, the cost of a wrong sequence is wasted effort. You can recover, reorder, and try again with limited damage. In the NHS, in financial services, in any market governed by procurement frameworks, clinical safety cases, or statutory approval, the cost of a wrong sequence is a closed door. A stakeholder who was approached too early, with the wrong evidence, rarely gives you a second chance to make a first impression. The relationship is spent before the proposition is ready.
The constraint is rarely effort
When we sit down with a founder or an executive team preparing for regulated market entry, the conversation almost always starts with a list of things they have already done. New hires, agency retainers, a refreshed brand, a pilot programme. All of it represents real work. Very little of it, on its own, represents progress.
That is because effort and direction are different problems. A team can be working extremely hard, hitting every deadline it sets itself, and still be moving in a sequence the market will not reward. The market does not care how much was done. It cares whether the right people were engaged, in the right order, with evidence that actually answers the question they are asking.
This is where advisory support earns its place, or fails to. The value is not in doing more work on the client's behalf. It is in helping the leadership team see, with more clarity than they can generate internally, what the constraint actually is. Usually it is not resource. It is decision quality at the point where the business chooses what to do next.
Three questions that expose the real problem
Strip away the activity and most regulated market entry problems reduce to three questions that are rarely asked explicitly inside the business, because everyone is too close to the work to step back and ask them.
Which stakeholder has to move first, and why does the sequence matter more than the individual conversations? In frameworks like NHS procurement, one relationship unlocking too early, before the evidence base is ready, can do more damage than no relationship at all. A clinical lead who hears a half-formed pitch remembers the half-formed pitch, not the finished product that arrives six months later.
What evidence needs to exist before the proposition is pushed harder? This is not a generic evidence question. It is specific to the audience, the framework, and the stage of the buying decision. A commissioner needs different proof than a clinical safety officer, who needs different proof again from a procurement lead running a formal tender. Businesses that treat evidence as a single pack, built once and reused everywhere, are answering questions nobody in the room actually asked.
What would make the route commercially credible, rather than simply active? Credibility in a regulated market is not built by presence. It is built by demonstrating that the business understands the system it is trying to enter: the incentives, the risk appetite, the political constraints each stakeholder is operating under. A business can be highly active in a market and still read as naive to the people who decide whether it gets through.
Why more resource does not solve this
The instinctive response to a stalled market entry is to add resource. A specialist agency for market access. A contractor with NHS experience. A part-time commercial hire who has "done this before" at a different company. Each of these can create useful output. None of them, on their own, changes the quality of the decisions being made at the top of the business.
That is the distinction worth holding onto. Output is easy to generate and easy to point to when a board asks what has been done this quarter. Direction is harder to demonstrate and far more valuable, because direction is what determines whether the output compounds into commercial traction or simply accumulates as activity nobody quite trusts.
A part-time hire, however experienced, is generally solving for their own function. A specialist agency is generally solving for the brief they were given, which is only as good as the sequencing decisions that shaped it. Neither is positioned to challenge the leadership team's underlying read of the market, because neither sits close enough to the table where that read is actually formed.
What a board-level relationship changes
The value of an embedded advisory relationship is proximity combined with seniority. Proximity means understanding the actual pressure the business is under, not a summarised version relayed in a monthly update. Seniority means having done this before, in enough different regulated contexts, to recognise when a leadership team is about to repeat a mistake that looks, from the inside, like sensible caution or sensible ambition.
That combination changes three things in practice. It reduces the number of disconnected workstreams running in parallel, because someone in the room is willing to say that two of the five current initiatives are not equally viable and one of them should stop. It tightens market sequencing, because the advisory relationship is not attached to any single function and can see the whole approach rather than defending one part of it. And it creates a clearer, more honest link between strategy, market access, and revenue, because the same people are accountable for all three rather than handing the business off between specialists who never quite see the full picture.
Where progress actually starts
The businesses that make faster, more durable progress in regulated markets are rarely the ones that added the most activity. They are the ones that improved the quality of thinking at the point where decisions get made, then let that better thinking shape what activity was worth doing next.
That is not a case against agencies, contractors, or new hires. All of them can be exactly the right answer, at the right moment, once the sequencing and the evidence requirements are clear. The mistake is reaching for them as a substitute for the harder, less visible work of getting the top-table judgement right first.
For a leadership team weighing regulated market entry, the more useful question is rarely "who can we bring in to do more." It is "who is close enough to this business, and senior enough in this kind of market, to help us decide what to do next, and just as importantly, what to stop doing." That is where the real constraint usually lives, and it is where progress usually starts.
